Company — Prothena
Advancing and developing novel antibodies for a broad range of diseases involving protein misfolding or cell adhesion, including amyloidosis. (NASDAQ: PRTA)
Advancing and developing novel antibodies for a broad range of diseases involving protein misfolding or cell adhesion, including amyloidosis. (NASDAQ: PRTA)